Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Ölpreisrutsch beflügelt Virgin Australia: Aktie springt an die ASX 200-Spitze (Investing.com DE) +++ VIRGIN AUSTRALIA Aktie +8,06%

BIOMARIN Aktie

 >BIOMARIN Aktienkurs 
49.45 EUR    -3.7%    (TradegateBSX)
Ask: 49.9 EUR / 113 Stück
Bid: 49.41 EUR / 114 Stück
Tagesumsatz: 100 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
BIOMARIN Aktie über LYNX handeln
>BIOMARIN Performance
1 Woche: +2,6%
1 Monat: +0,5%
3 Monate: -4,4%
6 Monate: +9,7%
1 Jahr: +14,4%
laufendes Jahr: +0,6%
>BIOMARIN Aktie
Name:  BIOMARIN PHARMACEUTICAL INC.
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US09061G1013 / 924801
Symbol/ Ticker:  BM8 (Frankfurt) / BMRN (NASDAQ)
Kürzel:  FRA:BM8, ETR:BM8, BM8:GR, NASDAQ:BMRN
Index:  -
Webseite:  https://www.biomarin.com/
Profil:  BioMarin Pharmaceutical Inc. is a global biotechnology company focused on developing and commercializing therapies for rare genetic and metabolic diseases. Its portfolio includes approved medicines and advanced treatments such as enzyme replacement t..
>Volltext..
Marktkapitalisierung:  10148.38 Mio. EUR
Unternehmenswert:  13080.28 Mio. EUR
Umsatz:  3097.37 Mio. EUR
EBITDA:  710.11 Mio. EUR
Nettogewinn:  65.38 Mio. EUR
Gewinn je Aktie:  0.34 EUR
Schulden:  3779.17 Mio. EUR
Liquide Mittel:  783.13 Mio. EUR
Operativer Cashflow:  767.97 Mio. EUR
Bargeldquote:  0.53
Umsatzwachstum:  17.26%
Gewinnwachstum:  -88.55%
Dividende je Aktie:  -
Dividendenrendite:  -
Dividendenschätzung:  -
Insiderhandel:  -
Suchwörter:  BIOMARIN
Letzte Datenerhebung:  03.11.26
>BIOMARIN Kennzahlen
Aktien/ Unternehmen:
Aktien: 193.57 Mio. St.
Frei handelbar: 98.71%
Leerverk. Aktien: 6.23%
Rückkaufquote: -0.12%
Mitarbeiter: 3221
Umsatz/Mitarb.: 0.9 Mio. EUR
Analysten:
Analystenrating: Buy
Kursziel: 65.28%
Bewertung:
KGV: 151.96
KGV lG: 15.61
KUV: 3.06
KBV: 1.73
PEG-Ratio: -
EV/EBITDA: 18.42
Rentabilität:
Bruttomarge: 73.93%
Gewinnmarge: 2.11%
Operative Marge: 18.5%
Managementeffizenz:
Gesamtkaprendite: 0.76%
Eigenkaprendite: 1.18%
>BIOMARIN Peer Group
Gesundheit, Stoffwechselerkrankungen (Diabetes/ Adipositas), Zell- & Gentherapie/ Gentechnik/ Erbkrankheiten
 
03.11.26 - 07:06
 BioMarin anticipates $3.8B-$3.9B 2026 revenue while flagging $70M order deferrals (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
03.11.26 - 05:36
 BioMarin (BMRN) Q3 2026 Earnings Call Transcript (Fool)
 
Revenue topped $1 billion for first time, fueled by Amicus integration....
03.11.26 - 01:30
 BioMarin (BMRN) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
 
The headline numbers for BioMarin (BMRN) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals....
03.11.26 - 01:18
 Earnings Call: BioMarin übertrifft Prognosen für Q3 2026 – Aktie fällt nach gesenktem Jahresausblick (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
02.11.26 - 22:12
 BioMarin Pharmaceutical Non-GAAP EPS of $0.23 beats by $0.34, revenue of $1.03B beats by $10M (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
02.11.26 - 22:06
 BioMarin Reports Third Quarter 2026 Financial and Operating Results (PR Newswire)
 
Third Quarter 2026 Total Revenues Increased 32% Y/Y to $1.025 billion; Growth Driven by 44% Increase in Metabolic Conditions Y/Y, and 12% Increase in Skeletal Conditions Y/Y Updates Full-year 2026 Guidance to Reflect Order Timing Uncertainty and Impact of Two Acquired In-process Research......
02.11.26 - 04:36
 Ihre wichtigsten Termine: Frische Q-Zahlen von Apple, Palantir, BioMarin, Marriott International, Fox Corp (Wallstreet-Online)
 
Gut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag....
30.10.26 - 18:24
 BioMarin Pharmaceutical Q3 2026 Earnings Preview (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
29.10.26 - 13:48
 BioMarin Enters Into Exclusive Worldwide License Agreement With GC Biopharma and Hanmi Pharm for Investigational Next-Generation Enzyme Replacement Therapy, Adding a Second Potential Treatment for Fabry Disease (PR Newswire)
 
Agreement grants BioMarin worldwide rights (excluding Korea) to HM15421/GC1134A, a long-acting, subcutaneous, clinical-stage enzyme replacement therapy for Fabry disease BioMarin will make an upfront payment of $70 million; GC and Hanmi will be jointly eligible to receive additional......
19.10.26 - 17:30
 BioMarin Pharmaceutical (BMRN) Earnings Expected to Grow: Should You Buy? (Zacks)
 
BioMarin (BMRN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations....
12.10.26 - 12:01
 BioMarin-Aktie legt zu: Analystenlob und positive Studiendaten geben Auftrieb (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
09.10.26 - 15:12
 BioMarin Presents New Data Advancing Understanding of Achondroplasia and Hypochondroplasia Treatment at the American Society for Bone and Mineral Research Annual Meeting (PR Newswire)
 
New analysis showcases impact of VOXZOGO® (vosoritide) in foramen magnum and craniocervical junction growth in children with achondroplasia, including infants SAN RAFAEL, Calif., Oct. 9, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced it will present new......
07.10.26 - 00:33
 BioMarin Q3 financial results to see IPR&D expense impact of $283M (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
06.10.26 - 22:36
 CNBC′s Becky Quick to Moderate CEO Leadership Dialogue on the Next Decade of Rare Disease at the NORD Breakthrough Summit (PR Newswire)
 
BioMarin, Jazz Pharmaceuticals, and Otsuka CEOs to Join NORD CEO to Examine What it Takes to Turn Scientific Advancements into Patient Progress WASHINGTON, Oct. 6, 2026 /PRNewswire/ -- The National Organization for Rare Disorders (NORD®) today announced that CNBC "Squawk Box" co-anchor......
05.10.26 - 22:12
 BioMarin Appoints Cara Bauer as Chief People Officer (PR Newswire)
 
Ms. Bauer Brings More Than 25 Years of Experience in Human Resources, Across Biotechnology and Technology Industries Appointment Effective Oct. 5, 2026 SAN RAFAEL, Calif., Oct. 5, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that Cara Bauer, Ph.D., has......
02.10.26 - 17:03
 BioMarin Announces Five-Year Phase 3 Data for POMBILITI® (cipaglucosidase alfa-atga) + OPFOLDA® (miglustat) at World Muscle Society Annual Congress (PR Newswire)
 
Long-term data reinforce durable efficacy and safety of POMBILITI + OPFOLDA in late-onset Pompe disease SAN RAFAEL, Calif., Oct. 2, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced new data evaluating the efficacy and safety of POMBILITI® (cipaglucosidase......
01.10.26 - 11:48
 BioMarin and Profluent partner on AI-designed enzyme therapies (PBR)
 
Under the agreement, Profluent will deploy its proprietary suite of protein language models to generate new potential drug candidates. BioMarin will screen and evaluate the computational outputs to The post BioMarin and Profluent partner on AI-designed enzyme therapies appeared first on Pharmaceutical Business review....
21.09.26 - 22:09
 Travere Therapeutics Announces Planned Chief Executive Officer Transition (Business Wire)
 
Eric Dube, Ph.D., has decided to step down as President and Chief Executive Officer in December Following Eight Years of Exemplary LeadershipBradley L. Campbell to be Appointed President and CEO Effective December 1, 2026SAN DIEGO--(BUSINESS WIRE)--$TVTX--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that Eric Dube, Ph.D., has made the difficult and personal decision to step down as president and chief executive officer to focus on his health and family. The Company's Board of Directors has unanimously appointed Bradley L. Campbell, former president and CEO of Amicus Therapeutics, now a wholly owned subsidiary of BioMarin Pharmaceutical Inc., to succeed Dr. Dube as president and chief executive officer and a member of the Board, effective December 1, 2026. Dr. Dube will continue to serve as president and chief executive officer until that date and will remain employed by the Company as executive advisor through February 15, 2027, to support an orderly transition.“Leading Travere has been th...
16.09.26 - 19:45
 BioMarin Stops Voxzogo Development for Noonan Syndrome (Zacks)
 
BMRN ends Voxzogo development for Noonan syndrome as the drug faces new competition and pursues other growth opportunities....
15.09.26 - 15:12
 BioMarin halts studies for Voxzogo in Noonan syndrome (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Der Bock ist ein Tier, welches auch als Bier getrunken werden kann. - Wilhelm Busch
>Aktienauflistung | >Aktienscreener | >Aktienkennzahlen | >Anleihen | >ETFs | >Fonds | >Branchen | >Länder | >Themen | >Redaktionen
Partner:    >TradegateBSX Börse | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!